A triple-drug treatment regimen to accelerate elimination of lymphatic filariasis: From conception to delivery

被引：16

作者：

Weil, Gary J. ^{[1
]}

Jacobson, Julie A. ^{[2
]}

King, Jonathan D. ^{[3
]}

机构：

[1] Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA

[2] Bridges Dev, Seattle, WA USA

[3] WHO, Dept Control Neglected Trop Dis, Geneva, Switzerland

来源：

INTERNATIONAL HEALTH | 2021年 / 13卷

基金：

比尔及梅琳达.盖茨基金会;

关键词：

elimination; ivermectin; lymphatic filariasis; mass drug administration; therapy;

D O I：

10.1093/inthealth/ihaa046

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

1004 ; 120402 ;

摘要：

The Global Programme to Eliminate Lymphatic Filariasis (LF) is usingmass drug administration (MDA) of antifilarialmedications to treat filarial infections, prevent disease and interrupt transmission. Almost 500 million people receive these medications each year. Clinical trials have recently shown that a single dose of a triple-drug combination comprised of ivermectin, diethylcarbamazine and albendazole (IDA) is dramatically superior to widely used two-drug combinations for clearing larval filarial parasites from the blood of infected persons. A large multicenter community study showed that IDA was well-tolerated when it was provided as MDA. IDA was rapidly advanced from clinical trial to policy and implementation; it has the potential to accelerate LF elimination in many endemic countries.

引用

页码：S60 / S64

页数：5

共 18 条

[1] GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 1: Introduction [J].

Alonso-Coello, Pablo ;

Schunemann, Holger J. ;

Moberg, Jenny ;

Brignardello-Petersen, Romina ;

Akl, Elie A. ;

Davoli, Marina ;

Treweek, Shaun ;

Mustafa, Reem A. ;

Rada, Gabriel ;

Rosenbaum, Sarah ;

Morelli, Angela ;

Guyatt, Gordon H. ;

Oxman, Andrew D. .

BMJ-BRITISH MEDICAL JOURNAL, 2016, 353

[2]

[Anonymous], 2012, HDB GUID DEV

[3] Efficacy and Safety of a Single Dose of Ivermectin, Diethylcarbamazine, and Albendazole for Treatment of Lymphatic Filariasis in Cote d'Ivoire: An Open-label Randomized Controlled Trial [J].

Bjerum, Catherine M. ;

Ouattara, Allassane F. ;

Aboulaye, Meite ;

Kouadio, Olivier ;

Marius, Vanga K. ;

Andersen, Britt J. ;

Weil, Gary J. ;

Koudou, Benjamin G. ;

King, Christopher L. .

CLINICAL INFECTIOUS DISEASES, 2020, 71 (07) :E68-E75

[4] Dosing pole recommendations for lymphatic filariasis elimination: A height-weight quantile regression modeling approach [J].

Goss, Charles W. ;

O'Brian, Katiuscia ;

Dubray, Christine ;

Fischer, Peter U. ;

Hardy, Myra ;

Jambulingam, Purushothaman ;

King, Christopher L. ;

Laman, Moses ;

Lemoine, Jean Frantz ;

Robinson, Leanne J. ;

Samuela, Josaia ;

Subramanian, Swaminathan ;

Supali, Taniawati ;

Weil, Gary J. ;

Schechtman, Kenneth B. .

PLOS NEGLECTED TROPICAL DISEASES, 2019, 13 (07)

[5]

Hoerauf Achim, 2002, Curr Opin Investig Drugs, V3, P533

[6] Single-Dose Triple-Drug Therapy for Wuchereria bancrofti-5-Year Follow-up [J].

King, Christopher L. ;

Weil, Gary J. ;

Kazura, James W. .

NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (20) :1956-1957

[7]

King CL, 2018, NEW ENGL J MED, V379, P1801, DOI [10.1056/NEJMoa1706854, 10.1056/nejmoa1706854]

[8]

Krentel A, 2018, ACCEPTABILITY TRIPLE

[9]

Merck SD, PROGRAM EXPANDED REA

[10] Predicting lymphatic filariasis transmission and elimination dynamics using a multi-model ensemble framework [J].

Smith, Morgan E. ;

Singh, Brajendra K. ;

Irvine, Michael A. ;

Stolk, Wilma A. ;

Subramanian, Swaminathan ;

Hollingsworth, T. Deirdre ;

Michael, Edwin .

EPIDEMICS, 2017, 18 :16-28

← 1 2 →